08:39 AM EST, 03/05/2024 (MT Newswires) -- Regenxbio ( RGNX ) reported new data Tuesday about its investigational gene therapy RGX-202 showing "significantly increased" microdystrophin expression at dose level 2 with early evidence of strength and motor function improvement in a 12-year-old patient with Duchenne muscular dystrophy.

The company said the patient's microdystrophin expression was 75.7% at three months, while lower serum creatinine kinase levels were recorded at 10 weeks. All four patients who completed the three-month trial assessments also showed higher microdystrophin expression and reduced serum creatinine kinase levels, the company added.

Regenxbio ( RGNX ) also said the new data showed that RGX-202 demonstrated "no drug-related serious adverse events" and was "well tolerated" by the participants.

The company said it intends to report strength and functional assessment data for both dose levels and launch a pivotal trial in H2.

Shares of the company increased 24% in recent premarket activity.

Price: 26.52, Change: +5.16, Percent Change: +24.14